A Phase 2 interventional study of Nivolumab and Anastrozole in Breast Cancer and Cancer, sponsored by Bristol-Myers Squibb. Completed at 36 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-10.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing nivolumab in Breast Neoplasms — 1 open to participants now, 8 under way, none of them phase 3. Nivolumab · Breast Neoplasms.
Among the 22 studies testing nivolumab in Breast Neoplasms, this one is the 16th largest by enrollment, is one of 10 that started in 2019, is one of 15 in phase 2, and was the 21st registered.
14,832 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →1 of the 22 studies testing nivolumab in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18+ · Women only
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 18 · Phase 3 1
First in 2015; this study’s year is marked. 10 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 47 across the 22 interventional studies. Of the 13 that completed or were terminated, 7 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 22 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
44 studies in Breast Neoplasms by Bristol-Myers Squibb: 4 open now, 4 under way, 1 of them phase 3. Of 39 finished, 20 (51%) have results posted.
Among the 44 studies in Breast Neoplasms by Bristol-Myers Squibb, this one is the 35th largest by enrollment of the 40 interventional ones that give a count, is one of 2 that started in 2019, is one of 23 in phase 2, and was the 38th registered.
Bristol-Myers Squibb’s Breast Neoplasms studies by the year they started, since 2001.
1 of the studies testing nivolumab in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03546686University of Texas Southwestern Medical CenterPeri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies testing nivolumab in Breast Neoplasms, from their registry updates:
Among Bristol-Myers Squibb’s 44 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
A randomized multi-arm study evaluating the safety and efficacy of palbociclib and anastrozole with or without nivolumab in participants with ER+/HER2- breast cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com.
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Nivolumab · Drug: Anastrozole · Drug: Palbociclib
Biological: Nivolumab · Drug: Anastrozole · Drug: Palbociclib
Drug: Anastrozole · Drug: Palbociclib
Specified Dose on Specified Days
Specified Dose on Specified Days
Specified Dose on Specified Days
The Number of Participants With Dose Limiting Toxicities (DLT) in the Safety Run-in Phase
The number of participants with dose limiting toxicities (DLTs) during the safety run-in phase. DLTS are defined as treatment emergent adverse events (TEAE) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 that occurs during the first 4 weeks (1 cycle) after treatment. Participants who withdraw from the study during the DLT evaluation period or have received less than 1 dose of nivolumab and 75% of accumulative doses of palbociclib of the cycle for reasons other than a DLT will not be considered as DLT-evaluable participants.
Time frame: From first dose to 4 weeks after first dose
Residual Cancer Burden (RCB) 0-1 Rate in the Randomized Phase
RCB 0-I rate is defined as the percentage of randomized participants who achieve RCB 0: no residual disease or RCB-I: minimal residual disease. RCB is a continuous index combining pathological measurements of primary tumor (size and cellularity) and nodal metastases (number and size) defined by a point system at surgery. No participants continued to the randomized phase; trial was closed after completion of the Safety Run-in.
Time frame: From randomization phase up to 5 treatment cycles (up to approximately 20 weeks)
Objective Response Rate (ORR)
ORR is defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) per investigator radiographic assessment. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From first dose up to approximately 6 months after first dose
Breast Conserving Surgery (BCS) Rate
The percentage of participants who undergo breast conserving surgery (BCS) after completing the study treatments. Confidence interval based on the Clopper and Pearson method.
Time frame: From first dose up to approximately 6 months after first dose
Pathological Complete Response (pCR) Rate
The percentage of participants with an absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy. Confidence interval based on the Clopper and Pearson method.
Time frame: From first dose up to approximately 6 months after first dose
The Number of Participants Experiencing Adverse Events (AEs)
The number of participants experiencing adverse events (AEs). An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
Time frame: From first dose to 30 days after last dose of study therapy (up to approximately 6 months)
The Number of Participants Experiencing Serious Adverse Events (SAEs)
The number of participants experiencing serious adverse events (SAEs). A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.
Time frame: From first dose to 30 days after last dose of study therapy (up to approximately 6 months)
The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation
The number of participants experiencing adverse events (AEs) that lead to discontinuation of study treatment. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
Time frame: From first dose to 30 days after last dose of study therapy (up to approximately 6 months)
The Number of Participants Experiencing Immune-Related Adverse Events (AEs)
The number of participants experiencing adverse events that are immune-related. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
Time frame: From first dose to 100 days after last dose of study therapy (up to approximately 8 months)
The Number of Participants Deaths
The number of participants that have died during the study.
Time frame: From first dose up to approximately 8 months
The Number of Participants Experiencing Laboratory Abnormalities in Specific Thyroid Tests - SI Units
The number of participants with laboratory abnormalities in specific thyroid tests based on SI conventional units. TSH = Thyroid Stimulating Hormone LLN = Lower Limit of Normal ULN = Upper Limit of Normal
Time frame: From first dose to 30 days after last dose of study therapy (up to approximately 6 months)
The Number of Participants Experiencing Laboratory Abnormalities in Specific Liver Tests
The number of participants with laboratory abnormalities in specific liver tests based on SI conventional units. ALT = Alanine Aminotransferase AST = Aspartate Aminotransferase ULN = Upper Limit of Normal
Time frame: From first dose to 30 days after last dose of study therapy (up to approximately 6 months)
| Milestone | Cohort 1: Dose Level 1 | Cohort 2: Dose Level 1 | Cohort 2: Dose Level 2 |
|---|---|---|---|
| Started | 2 | 9 | 12 |
| Completed | 1 | 3 | 6 |
| Not completed | 1 | 6 | 6 |
| Withdrew: Adverse event | 0 | 0 | 3 |
| Withdrew: Participant request to discontinue study treatment | 0 | 0 | 1 |
| Withdrew: Participant withdrew consent | 0 | 0 | 1 |
| Withdrew: Other reasons | 1 | 0 | 0 |
| Withdrew: Disease progression | 0 | 1 | 0 |
| Withdrew: Study drug toxicity | 0 | 5 | 1 |
The number of participants with dose limiting toxicities (DLTs) during the safety run-in phase. DLTS are defined as treatment emergent adverse events (TEAE) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 that occurs during the first 4 weeks (1 cycle) after treatment. Participants who withdraw from the study during the DLT evaluation period or have received less than 1 dose of nivolumab and 75% of accumulative doses of palbociclib of the cycle for reasons other than a DLT will not be considered as DLT-evaluable participants.
| Participants | Cohort 1: Dose Level 1 | Cohort 2: Dose Level 1 | Cohort 2: Dose Level 2 |
|---|---|---|---|
| The Number of Participants With Dose Limiting Toxicities (DLT) in the Safety Run-in Phase | 0 | 2 | 0 |
RCB 0-I rate is defined as the percentage of randomized participants who achieve RCB 0: no residual disease or RCB-I: minimal residual disease. RCB is a continuous index combining pathological measurements of primary tumor (size and cellularity) and nodal metastases (number and size) defined by a point system at surgery. No participants continued to the randomized phase; trial was closed after completion of the Safety Run-in.
No measurements were reported for this outcome.
ORR is defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) per investigator radiographic assessment. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| Percentage of Participants | Cohort 1: Dose Level 1 | Cohort 2: Dose Level 1 | Cohort 2: Dose Level 2 |
|---|---|---|---|
| Objective Response Rate (ORR) | 0.0 (0.0 to 84.2) | 66.7 (29.9 to 92.5) | 75.0 (42.8 to 94.5) |
The percentage of participants who undergo breast conserving surgery (BCS) after completing the study treatments. Confidence interval based on the Clopper and Pearson method.
| Percentage of Participants | Cohort 1: Dose Level 1 | Cohort 2: Dose Level 1 | Cohort 2: Dose Level 2 |
|---|---|---|---|
| Breast Conserving Surgery (BCS) Rate | 50.0 (1.3 to 98.7) | 55.6 (21.2 to 86.3) | 50.0 (21.1 to 78.9) |
The percentage of participants with an absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy. Confidence interval based on the Clopper and Pearson method.
| Percentage of Participants | Cohort 1: Dose Level 1 | Cohort 2: Dose Level 1 | Cohort 2: Dose Level 2 |
|---|---|---|---|
| Pathological Complete Response (pCR) Rate | 0.0 (0.0 to 84.2) | 0.0 (0.0 to 33.6) | 8.3 (0.2 to 38.5) |
The number of participants experiencing adverse events (AEs). An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
| Participants | Cohort 1: Dose Level 1 | Cohort 2: Dose Level 1 | Cohort 2: Dose Level 2 |
|---|---|---|---|
| The Number of Participants Experiencing Adverse Events (AEs) | 2 | 9 | 12 |
The number of participants experiencing serious adverse events (SAEs). A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.
| Participants | Cohort 1: Dose Level 1 | Cohort 2: Dose Level 1 | Cohort 2: Dose Level 2 |
|---|---|---|---|
| The Number of Participants Experiencing Serious Adverse Events (SAEs) | 0 | 5 | 2 |
The number of participants experiencing adverse events (AEs) that lead to discontinuation of study treatment. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
| Participants | Cohort 1: Dose Level 1 | Cohort 2: Dose Level 1 | Cohort 2: Dose Level 2 |
|---|---|---|---|
| The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 0 | 5 | 4 |
The number of participants experiencing adverse events that are immune-related. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
| Participants | Cohort 1: Dose Level 1 | Cohort 2: Dose Level 1 | Cohort 2: Dose Level 2 |
|---|---|---|---|
| Hypothyroidism | 1 | 0 | 0 |
| Hyperthyroidism | 0 | 0 | 1 |
| Immune-mediated lung disease | 0 | 1 | 0 |
| Pneumonitis | 0 | 0 | 1 |
| Hepatitis | 0 | 3 | 2 |
| Rash | 0 | 2 | 0 |
The number of participants that have died during the study.
| Participants | Cohort 1: Dose Level 1 | Cohort 2: Dose Level 1 | Cohort 2: Dose Level 2 |
|---|---|---|---|
| The Number of Participants Deaths | 0 | 0 | 0 |
The number of participants with laboratory abnormalities in specific thyroid tests based on SI conventional units. TSH = Thyroid Stimulating Hormone LLN = Lower Limit of Normal ULN = Upper Limit of Normal
| Participants | Cohort 1: Dose Level 1 | Cohort 2: Dose Level 1 | Cohort 2: Dose Level 2 |
|---|---|---|---|
| TSH > ULN | 1 | 3 | 2 |
| TSH > ULN WITH TSH <= ULN AT BASELINE | 1 | 2 | 1 |
| TSH >ULN WITH ATLEAST ONE FT3/FT4 TEST VALUE <LLN | 0 | 1 | 2 |
| TSH >ULN WITH ALL OTHER FT3/FT4 TEST VALUES >= LLN | 0 | 2 | 2 |
| TSH > ULN WITH FT3/FT4 TEST MISSING | 1 | 0 | 0 |
| TSH < LLN | 0 | 3 | 4 |
| TSH <LLN WITH TSH >= LLN AT BASELINE | 0 | 2 | 4 |
| TSH <LLN WITH ATLEAST ONE FT3/FT4 TEST VALUE > ULN | 0 | 1 | 1 |
| TSH <LLN WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN | 0 | 1 | 3 |
| TSH < LLN WITH FT3/FT4 TEST MISSING | 0 | 1 | 0 |
The number of participants with laboratory abnormalities in specific liver tests based on SI conventional units. ALT = Alanine Aminotransferase AST = Aspartate Aminotransferase ULN = Upper Limit of Normal
| Participants | Cohort 1: Dose Level 1 | Cohort 2: Dose Level 1 | Cohort 2: Dose Level 2 |
|---|---|---|---|
| ALT OR AST > 3XULN | 0 | 4 | 3 |
| ALT OR AST > 5XULN | 0 | 3 | 3 |
| ALT OR AST > 10XULN | 0 | 2 | 2 |
| ALT OR AST > 20XULN | 0 | 1 | 2 |
| TOTAL BILIRUBIN > 2XULN | 0 | 0 | 0 |
| ALP > 1.5XULN | 0 | 3 | 1 |
| ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>1.5XULN IN 1 DAY | 0 | 1 | 1 |
| ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>1.5XULN IN 30 DAYS | 0 | 1 | 1 |
| ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 1 DAY | 0 | 0 | 0 |
| ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 30 DAYS | 0 | 0 | 0 |
Collected over Adverse Events (AEs) were monitored from first dose to 100 days after last dose of study therapy (up to approximately 8 months). Serious Adverse events were monitored between first dose and 30 days after last dose of study therapy. (Up to approximately 6 months) Participants were assessed for All Cause Mortality from their first dose until the study was completed (up to approximately 21 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Dose Level 1 | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Cohort 2: Dose Level 1 | 0/9 (0%) | 5/9 (55.6%) | 8/9 (88.9%) |
| Cohort 2: Dose Level 2 | 0/12 (0%) | 3/12 (25%) | 12/12 (100%) |
| Event | Cohort 1: Dose Level 1 | Cohort 2: Dose Level 1 | Cohort 2: Dose Level 2 |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/2 | 1/9 | 0/12 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/2 | 1/9 | 0/12 |
| Atrial fibrillationCardiac disorders | 0/2 | 1/9 | 0/12 |
| HepatitisHepatobiliary disorders | 0/2 | 1/9 | 0/12 |
| Alanine aminotransferase increasedInvestigations | 0/2 | 1/9 | 0/12 |
| Aspartate aminotransferase increasedInvestigations | 0/2 | 1/9 | 0/12 |
| Immune-mediated lung diseaseRespiratory, thoracic and mediastinal disorders | 0/2 | 1/9 | 0/12 |
| RashSkin and subcutaneous tissue disorders | 0/2 | 1/9 | 0/12 |
| HypertransaminasaemiaHepatobiliary disorders | 0/2 | 0/9 | 1/12 |
| Second primary malignancyNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/2 | 0/9 | 1/12 |
| Event | Cohort 1: Dose Level 1 | Cohort 2: Dose Level 1 | Cohort 2: Dose Level 2 |
|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 2/2 | 1/9 | 3/12 |
| HypothyroidismEndocrine disorders | 1/2 | 0/9 | 1/12 |
| Vision blurredEye disorders | 1/2 | 0/9 | 0/12 |
| Abdominal painGastrointestinal disorders | 1/2 | 0/9 | 1/12 |
| DiarrhoeaGastrointestinal disorders | 1/2 | 2/9 | 1/12 |
| NauseaGastrointestinal disorders | 1/2 | 1/9 | 1/12 |
| VomitingGastrointestinal disorders | 1/2 | 0/9 | 1/12 |
| FatigueGeneral disorders | 1/2 | 2/9 | 5/12 |
| GastroenteritisInfections and infestations | 1/2 | 0/9 | 0/12 |
| Upper respiratory tract infectionInfections and infestations | 1/2 | 0/9 | 0/12 |
| Age, Continuous(Years) | Cohort 1: Dose Level 1 | Cohort 2: Dose Level 1 | Cohort 2: Dose Level 2 | Total |
|---|---|---|---|---|
| Mean | 63 ± 2.8 | 60.3 ± 9.3 | 67.4 ± 10.2 | 64.3 ± 9.8 |
| Age, Customized(Participants) | Cohort 1: Dose Level 1 | Cohort 2: Dose Level 1 | Cohort 2: Dose Level 2 | Total |
|---|---|---|---|---|
| < 65 | 1 | 7 | 5 | 13 |
| >= 65 AND < 75 | 1 | 1 | 3 | 5 |
| >= 75 AND < 85 | 0 | 1 | 4 | 5 |
| Sex: Female, Male(Participants) | Cohort 1: Dose Level 1 | Cohort 2: Dose Level 1 | Cohort 2: Dose Level 2 | Total |
|---|---|---|---|---|
| Female | 2 | 9 | 12 | 23 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: Dose Level 1 | Cohort 2: Dose Level 1 | Cohort 2: Dose Level 2 | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 2 | 4 |
| Not Hispanic or Latino | 2 | 5 | 7 | 14 |
| Unknown or Not Reported | 0 | 2 | 3 | 5 |
| Race (NIH/OMB)(Participants) | Cohort 1: Dose Level 1 | Cohort 2: Dose Level 1 | Cohort 2: Dose Level 2 | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 1 |
| White | 1 | 9 | 11 | 21 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2019 to primary completion in Jul 2021, 21 months.
Results were first posted in Aug 2022, 1 year after primary completion.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 21 months is below that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nivolumab